Long-term cognitive function changes and related factors in patients with prostate cancer treated by androgen deprivation therapy
10.3760/cma.j.cn115682-20210326-01350
- VernacularTitle:去势治疗前列腺癌患者长期认知功能变化情况及相关因素分析
- Author:
Ping LI
1
;
Jianxia CHEN
;
Jing CHEN
;
Zhenzhen JIN
;
Rongrong WU
;
Rong QIAN
Author Information
1. 温州医科大学附属第一医院泌尿外科，温州 325006
- Keywords:
Prostatic neoplasms;
Androgen deprivation therapy;
Cognitive function;
Influencing factors
- From:
Chinese Journal of Modern Nursing
2021;27(33):4531-4536
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate changes in long-term cognitive function of patients with prostate cancer treated by androgen deprivation therapy (ADT) and analyze its related factors.Methods:Using a prospective cohort study method, a total of 131 patients with non-metastatic prostate cancer who were admitted to the First Affiliated Hospital of Wenzhou Medical University from April 2016 to April 2018 were selected as the research objects. The patients who received ADT were set as the ADT group and the patients who did not use ADT were set as the non-ADT group. General Situation Questionnaire, Montreal Cognitive Assessment Basic Scale (MoCA-B) , Patient Health Questionnaire (PHQ-9) and Chinese version of Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) were used to investigate. Longitudinal comparisons of patients were made between the two groups on admission, 6 months later, 12 months later and 24 months later. Multivariate regression analysis was conducted to analyze factors associated with cognitive changes in prostate cancer patients receiving ADT.Results:At the end of the 24-month follow-up, a total of 123 patients had completed the investigation, including 55 in the ADT group and 68 in the non-ADT group. The FACT-Cog scores of patients in the ADT group were respectively (110.3±10.2) , (107.6±10.2) , (106.1±9.9) and (103.1±9.5) at the time of enrollment, 6 months, 12 months and 24 months. The FACT-Cog scores of patients in the non-ADT group were respectively (111.1±10.0) , (108.7±10.3) , (107.0±9.4) and (106.4±9.5) at the time of enrollment, 6 months, 12 months and 24 months. Multivariate analysis showed that treatment, age and PHQ-9 score were the influencing factors of cognitive decline in prostate cancer patients ( P<0.05) . Conclusions:The cognitive function of prostate cancer patients who have received ADT for a long time has declined over time. ADT, aging and depression are the main independent risk factors for cognitive decline, suggesting that nursing workers should pay attention to changes of cognitive function of patients at early stage and provide nursing intervention for risk factors to improve the cognitive status of patients.
